Atorvastatin administration is associated with dose-related changes in IGF bioavailability

Ram P. Narayanan, Matthew Gittins, Kirk W. Siddals, Robert L. Oliver, Julie E. Hudson, Anne White, Paul Durrington, Robert R. Davies, Martin Rutter, J. Martin Gibson

    Research output: Contribution to journalArticlepeer-review


    Objective: IGF levels, their binding proteins (IGFBPs) and high-dose statin therapy have been linked to the development of diabetes.We aimed to identify whether atorvastatin caused dose-related changes in IGF proteins. Design and methods: We measured IGF1, IGF2, IGFBP1 and IGFBP3 concentrations at baseline, 6 and 12 months in Protection Against Nephropathy in Diabetes with Atorvastatin trial participants with type 2 diabetes randomised to 10 mg (n=59) vs 80 mg (n=60) of atorvastatin (n=119; mean (S.D.): age 64 (10) years; 83% male; HbA1c 61 (10) mmol/mol; blood pressure 131/73 mmHg). Results: Atorvastatin was associated with overall reductions in circulating IGF1, IGF2 and IGFBP3 concentrations (P
    Original languageEnglish
    Pages (from-to)543-548
    Number of pages5
    JournalEuropean Journal of Endocrinology
    Issue number4
    Publication statusPublished - Apr 2013


    • Aged
    • Biological Availability
    • Diabetes Mellitus, Type 2/ blood/drug therapy
    • Dose-Response Relationship, Drug
    • Double-Blind Method
    • Female
    • Heptanoic Acids/ administration & dosage
    • Humans
    • Hydroxymethylglutaryl-CoA Reductase Inhibitors/administration & dosage
    • Insulin-Like Growth Factor Binding Protein 1/ blood
    • Insulin-Like Growth Factor Binding Protein 3/ blood
    • Insulin-Like Growth Factor I/ metabolism
    • Insulin-Like Growth Factor II/ metabolism
    • Male
    • Middle Aged
    • Pyrroles/ administration & dosage


    Dive into the research topics of 'Atorvastatin administration is associated with dose-related changes in IGF bioavailability'. Together they form a unique fingerprint.

    Cite this